However, she also received counseling for management of risk for other malignancies including colon cancer, pancreatic cancer, and melanoma based on the presence of concurrent pathogenic mutations in BRCA2 and CHEK2. This evidence concerns the gene BRCA2 and familial pancreatic carcinoma.